Centers for Medicare & Medicaid Services (CMS), HHS.
This proposed notice announces the application of the Utilization Review Accreditation Commission (URAC) for deeming authority as a national accreditation organization for prescription drug plan sponsors participating in the Voluntary Medicare Prescription Drug Benefit Program. This announcement describes the criteria to be used in evaluating the application and provides information for submitting comments during a 30 day public comment period.
To be assured consideration, comments must be received at one of the addresses provided below, no later than 5 p.m. on March 30, 2009.
In commenting, please refer to file code CMS-4142-PN. Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission.
You may submit comments in one of four ways (please choose only one of the ways listed):
1. Electronically. You may submit electronic comments on specific issues in this regulation to http://www.regulations.gov. Follow the instructions for “Comment of Submission” and enter the file code to find the document accepting comments.
2. By regular mail. You may mail written comments (one original and two copies) to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS-4142-PN, P.O. Box 8016, Baltimore, MD 21244-8016.
Please allow sufficient time for mailed comments to be received before the close of the comment period.Start Printed Page 8968
3. By express or overnight mail. You may send written comments (one original and two copies) to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS-4142-PN, Mail Stop C4-26-05, 7500 Security Boulevard, Baltimore, MD 21244-1850.
4. By hand or courier. If you prefer, you may deliver (by hand or courier) your written comments (one original and two copies) before the close of the comment period to one of the following addresses:
a. Room 445-G, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201
(Because access to the interior of the HHH Building is not readily available to persons without Federal Government identification, commenters are encouraged to leave their comments in the CMS drop slots located in the main lobby of the building. A stamp-in clock is available for persons wishing to retain a proof of filing by stamping in and retaining an extra copy of the comments being filed.)
b. 7500 Security Boulevard, Baltimore, MD 21244-1850.
If you intend to deliver your comments to the Baltimore address, please call telephone number (410) 786-7195 in advance to schedule your arrival with one of our staff members.
Comments mailed to the addresses indicated as appropriate for hand or courier delivery may be delayed and received after the comment period.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Sue Bradshaw, (410) 786-2896.End Further Info End Preamble Start Supplemental Information
Inspection of Public Comments: All comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following Web site as soon as possible after they have been received: http://www.regulations.gov. Follow the search instructions on that Web site to view public comments.
Comments received timely will also be available for public inspection as they are received, generally beginning approximately 3 weeks after publication of a document, at the headquarters of the Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Baltimore, Maryland 21244, Monday through Friday of each week from 8:30 a.m. to 4 p.m. To schedule an appointment to view public comments, phone 1-800-743-3951.
Under the Medicare program, eligible beneficiaries may receive prescription drug benefits through a Prescription drug plan (PDP) sponsor that has a prescription drug plan contract with the Centers for Medicare & Medicaid Services (CMS). The regulations specifying the Medicare requirements that must be met in order for a PDP sponsor to enter into a prescription drug plan contract with CMS are located at 42 CFR part 423. These requirements implement Part D of Title XVIII of the Social Security Act (the Act), which specifies the prescription drug benefits that a PDP sponsor must provide and the requirements that the organization must meet to be a PDP sponsor. Other relevant sections of the Act are parts A and B of Title XVIII and part A of Title XI of the Act, pertaining to the provision of services by Medicare certified providers and suppliers.
Generally, for an organization to enter into a PDP contract, the organization must be licensed by the State as a risk bearing organization as set forth at 42 CFR 423.504(b)(2) of our regulations. Additionally, the organization must file an application demonstrating that it meets other Medicare requirements in part 423 of our regulations. Following approval of the contract, we engage in routine monitoring and oversight audits of the PDP sponsors to ensure continuing compliance. The monitoring and oversight audit process is comprehensive and uses a written protocol that itemizes the Medicare requirements that the PDP sponsors must meet.
As an alternative for meeting some Medicare requirements, a PDP sponsor may be exempt from CMS monitoring of certain requirements in subsets listed in section 1860D-4(j) of the Act (cross-referencing section 1852(e)(4)(B) of the Act) as a result of a PDP sponsor's accreditation by a CMS-approved accrediting organization (AO). In essence, the Secretary “deems” that the PDP has met the Medicare requirements via its accreditation, based on a previous determination that the AO's standards are at least as stringent as Medicare requirements. As we specify at § 423.168(b)(2)(ii) of our regulations, the term for which an AO may be approved by CMS may not exceed 6 years. For continuing approval, the AO will have to re-apply to CMS. An organization that applies for PDP sponsor deeming authority is generally recognized by the industry as an entity that accredits PDP sponsors that are licensed as prescription drug plan sponsors. Section 1852(e)(4)(C) of the Act requires that within 210 days of receipt of an application, the Secretary shall determine whether the applicant meets criteria specified in section 1865(b)(2) (redesignated in 2008 as section 1865(a)(2)) of the Act.
On October 14, 2008 URAC submitted to CMS an application for deeming authority with respect to Part D sponsors' compliance with the following PDP plan requirements, as set out at 42 CFR 423.165(b):
▪ Access to covered drugs;
▪ Confidentiality and accuracy of enrollee prescription drug records;
▪ Drug utilization management, quality assurance measure and systems, medication therapy management; and,
▪ The sponsors' programs to control fraud, waste and abuse. To be approved for deeming authority, an accrediting organization must demonstrate that its accreditation program requirements meet or exceed the Medicare requirements for which it is seeking the authority to deem compliance.
II. Provisions of the Proposed Notice
The purpose of this proposed notice is to notify the public of the application of the Utilization Review Accreditation Commission for deeming authority as a national accreditation organization for prescription drug plan sponsors participating in the Voluntary Medicare Prescription Drug Benefit Program. This announcement describes the criteria to be used in evaluating the application and provides information for submitting comments during a 30-day public comment period.
Deeming Application Approval Process
The application process for deeming authority includes a review of URAC's application in accordance with the criteria specified by our regulations at § 422.171(a). This includes, but is not limited to, the following:
- The equivalency of URAC's requirements for PDP sponsors to CMS's comparable PDP sponsor requirements.
- URAC's survey process, to determine the following:
+ The frequency of surveys.
+ The types of forms, guidelines, and instructions used by surveyors.
+ Descriptions of the accreditation decision making process, deficiency notification and monitoring process, and compliance enforcement process.
- Detailed information about individuals who perform accreditation surveys including—
+ Size and composition of the survey team;
+ Education and experience requirements for the surveyors;
+ In-service training required for surveyor personnel;Start Printed Page 8969
+ Surveyor performance evaluation systems; and
+ Conflict of interest policies relating to individuals in the survey and accreditation decision process.
- Descriptions of the organization's—
+ Data management and analysis system;
+ Policies and procedures for investigating and responding to complaints against accredited organizations; and+ Types and categories of accreditation offered and PDP sponsors and MA organizations currently accredited within those types and categories.
In accordance with § 423.171(b) of our regulations, the applicant must provide documentation relating to the following:
- Its ability to provide data in a CMS compatible format.
- The adequacy of personnel and other resources necessary to perform the required surveys and other activities.
- Assurances that it will comply with ongoing responsibility requirements specified in § 423.168(c) of our regulations.
Additionally, the accrediting organization must provide CMS with the opportunity to observe its accreditation process on site at a managed care organization and must provide any other information that CMS requires to prepare for an onsite visit. These site visits will help to verify that the information presented in the application is correct and to make a determination on the application.
In accordance with section 1865(a)(3)(A) of the Act and our regulations at § 423.168(b)(1), this proposed notice solicits public comment on the ability of URAC's accreditation program to meet or exceed the Medicare requirements for PDP sponsors which it seeks authority to deem as being in compliance with such requirements. In accordance with § 423.168(b)(1)(iii), comments are due [at least 30] days after the date of publication of this proposed notice.
III. Collection of Information Requirements
This document does not impose information collection and recordkeeping requirements. Consequently, it need not be reviewed by the Office of Management and Budget under the authority of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35).
IV. Response to Comments
Because of the large number of public comments we normally receive on Federal Register documents, we are not able to acknowledge or respond to them individually. We will consider all comments we receive by the date and time specified in the DATES section of this preamble, and, when we proceed with a subsequent document, we will respond to the comments in the preamble to that document.
V. Regulatory Impact Statement
In accordance with the provisions of Executive Order 12866, this regulation was not reviewed by the Office of Management and Budget.
(Catalog of Federal Domestic Assistance Program No. 93.773, Medicare—Hospital Insurance Program; and No. 93.774, Medicare—Supplementary Medical Insurance Program)Start Signature
Dated: February 13, 2009.
Acting Administrator, Centers for Medicare & Medicaid Services.
[FR Doc. E9-4320 Filed 2-26-09; 8:45 am]
BILLING CODE 4120-01-P